EV-TRACK

Search > Results

You searched for: EV220043 (EV-TRACK ID)

Showing 1 - 4 of 4

Results list Study Tree

Details	EV-TRACK ID	Experiment nr.	Species	Sample type	Separation protocol	First author	Year	EV-METRIC
	EV220043	1/4	Homo sapiens	U-87MG	(d)(U)C Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	Yang T	2015	25%
Study summary Full title Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. All authors Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S Journal Pharm Res Abstract The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. (show more...)The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. This study tests the hypothesis that brain endothelial cell derived exosomes can deliver anticancer drug across the BBB for the treatment of brain cancer in a zebrafish (Danio rerio) model. (hide) EV-METRIC 25% (64th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Cell culture supernatant Sample origin Control condition Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture (Differential) (ultra)centrifugation Commercial method Protein markers EV: CD81/ CD63/ CD9 non-EV: None Proteomics no Show all info Study aim Function/Mechanism of uptake/transfer Sample Species Homo sapiens Sample Type Cell culture supernatant EV-producing cells U-87MG EV-harvesting Medium EV-depleted medium Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Between 800 g and 10,000 g Pelleting performed No Commercial kit Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen) Characterization: Protein analysis Protein Concentration Method BCA Western Blot Antibody details provided? No Not detected EV-associated proteins CD81/ CD63/ CD9 ELISA Antibody details provided? No Detected EV-associated proteins CD63/ CD81/ CD9 Characterization: Lipid analysis No Characterization: Particle analysis DLS Report type Not Reported EM EM-type Scanning-EM Image type Close-up, Wide-field

	EV220043	2/4	Homo sapiens	bEND.3	(d)(U)C Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	Yang T	2015	25%
Study summary Full title Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. All authors Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S Journal Pharm Res Abstract The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. (show more...)The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. This study tests the hypothesis that brain endothelial cell derived exosomes can deliver anticancer drug across the BBB for the treatment of brain cancer in a zebrafish (Danio rerio) model. (hide) EV-METRIC 25% (64th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Cell culture supernatant Sample origin Control condition Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture (Differential) (ultra)centrifugation Commercial method Protein markers EV: CD81/ CD63/ CD9 non-EV: None Proteomics no Show all info Study aim Function/Mechanism of uptake/transfer Sample Species Homo sapiens Sample Type Cell culture supernatant EV-producing cells bEND.3 EV-harvesting Medium EV-depleted medium Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Between 800 g and 10,000 g Pelleting performed No Commercial kit Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen) Characterization: Protein analysis Protein Concentration Method BCA Western Blot Antibody details provided? No Detected EV-associated proteins CD63 Not detected EV-associated proteins CD81/ CD9 ELISA Antibody details provided? No Detected EV-associated proteins CD63/ CD81/ CD9 Characterization: Lipid analysis No Characterization: Particle analysis DLS Report type Not Reported EM EM-type Scanning-EM Image type Close-up, Wide-field

	EV220043	3/4	Homo sapiens	PFSK-1	(d)(U)C Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	Yang T	2015	25%
Study summary Full title Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. All authors Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S Journal Pharm Res Abstract The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. (show more...)The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. This study tests the hypothesis that brain endothelial cell derived exosomes can deliver anticancer drug across the BBB for the treatment of brain cancer in a zebrafish (Danio rerio) model. (hide) EV-METRIC 25% (64th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Cell culture supernatant Sample origin Control condition Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture (Differential) (ultra)centrifugation Commercial method Protein markers EV: CD81/ CD63/ CD9 non-EV: None Proteomics no Show all info Study aim Function/Mechanism of uptake/transfer Sample Species Homo sapiens Sample Type Cell culture supernatant EV-producing cells PFSK-1 EV-harvesting Medium EV-depleted medium Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Between 800 g and 10,000 g Pelleting performed No Commercial kit Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen) Characterization: Protein analysis Protein Concentration Method BCA Western Blot Antibody details provided? No Not detected EV-associated proteins CD81/ CD63/ CD9 ELISA Antibody details provided? No Detected EV-associated proteins CD63/ CD81/ CD9 Characterization: Lipid analysis No Characterization: Particle analysis DLS Report type Mean Reported size (nm) 74.5 EM EM-type Scanning-EM Image type Close-up, Wide-field

	EV220043	4/4	Homo sapiens	A-172	(d)(U)C Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	Yang T	2015	25%
Study summary Full title Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. All authors Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S Journal Pharm Res Abstract The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. (show more...)The blood-brain barrier (BBB) essentially restricts therapeutic drugs from entering into the brain. This study tests the hypothesis that brain endothelial cell derived exosomes can deliver anticancer drug across the BBB for the treatment of brain cancer in a zebrafish (Danio rerio) model. (hide) EV-METRIC 25% (64th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Cell culture supernatant Sample origin Control condition Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture (Differential) (ultra)centrifugation Commercial method Protein markers EV: CD81/ CD63/ CD9 non-EV: None Proteomics no Show all info Study aim Function/Mechanism of uptake/transfer Sample Species Homo sapiens Sample Type Cell culture supernatant EV-producing cells A-172 EV-harvesting Medium EV-depleted medium Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Between 800 g and 10,000 g Pelleting performed No Commercial kit Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen) Characterization: Protein analysis Protein Concentration Method BCA Western Blot Antibody details provided? No Not detected EV-associated proteins CD81/ CD63/ CD9 ELISA Antibody details provided? No Detected EV-associated proteins CD63/ CD81/ CD9 Characterization: Lipid analysis No Characterization: Particle analysis DLS Report type Not Reported EM EM-type Scanning-EM Image type Close-up, Wide-field

				1 - 4 of 4

EV-TRACK ID	EV220043
species	Homo sapiens
sample type	Cell culture
cell type	U-87MG	bEND.3	PFSK-1	A-172
condition	Control condition	Control condition	Control condition	Control condition
separation protocol	dUC/ Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	dUC/ Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	dUC/ Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)	dUC/ Other/ Total Exosome RNA and Protein Isolation Kit (Invitrogen)
Exp. nr.	1	2	3	4
EV-METRIC %	25	25	25	25